Filter Results:
(5,523)
Show Results For
- All HBS Web
(5,523)
- People (17)
- News (2,102)
- Research (2,737)
- Events (3)
- Multimedia (223)
- Faculty Publications (2,085)
Show Results For
- All HBS Web
(5,523)
- People (17)
- News (2,102)
- Research (2,737)
- Events (3)
- Multimedia (223)
- Faculty Publications (2,085)
- Blog
The Chao Center: The Heart of HBS Executive Education
also supporting health care initiatives and U.S.-Asia cultural exchanges." In 2012, the Chao family donated US$40 million to Harvard Business School, supporting the construction of the Ruth Mulan Chu Chao... View Details
- 2020
- Working Paper
Bankruptcy and the COVID-19 Crisis
By: Jialan Wang, Jeyul Yang, Benjamin Iverson and Raymond Kluender
We examine the impact of the COVID-19 economic crisis on business and consumer bankruptcies in the United States using real-time data on the universe of filings. Historically, bankruptcies have closely tracked the business cycle and contemporaneous unemployment rates.... View Details
Keywords: Bankruptcy; Financial Distress; COVID-19; Insolvency and Bankruptcy; Financial Crisis; Health Pandemics; United States
Wang, Jialan, Jeyul Yang, Benjamin Iverson, and Raymond Kluender. "Bankruptcy and the COVID-19 Crisis." Harvard Business School Working Paper, No. 21-041, September 2020.
- December 2022
- Article
The Contribution of Price Growth to Pharmaceutical Revenue Growth in the United States: Evidence from Medicines Sold in Retail Pharmacies
By: Pragya Kakani, Michael Chernew and Amitabh Chandra
Context: To what extent does pharmaceutical revenue growth depend on new medicines versus increasing prices for existing medicines? Moreover, does using list prices, as is commonly done, instead of prices net of confidential rebates offered by manufacturers, which are... View Details
Kakani, Pragya, Michael Chernew, and Amitabh Chandra. "The Contribution of Price Growth to Pharmaceutical Revenue Growth in the United States: Evidence from Medicines Sold in Retail Pharmacies." Journal of Health Politics, Policy and Law 47, no. 6 (December 2022): 629–648.
- Web
Courses by Faculty Unit - Course Catalog
International Economy) Laura Alfaro Spring 2025 Q3 1.5 IFC: Ghana; Africa Rising Hakeem I. Belo-Osagie January 2025 J 3.0 IFC: India; Development While Decarbonizing - India’s Path to Net Zero (also listed under Entrepreneurial Management) Vikram Gandhi January 2025 J... View Details
Alvin E. Roth
Al Roth is the George Gund Professor of Economics and Business Administration in the Department of Economics at Harvard University, and in the Harvard Business School. His research, teaching, and consulting interests are in game theory, experimental economics, and... View Details
- Web
Interviewing - Alumni
valuable opportunity for me to understand the exciting projects already underway. As I mentioned, I continue to be extremely interested in Alpha Galactic, particularly the AGO Division. My consulting background and health View Details
- Web
Strategy for Universities & Nonprofits - Institute For Strategy And Competitiveness
customers must be quantified and measured Social organizations often pursue multiple societal outcomes , which requires multiple measured goals Understanding the full costs of delivering outcomes is essential to ensure that true value is being created, e.g. cost per... View Details
- Profile
Ted Obi
Why did you choose this path at this point in time? I halted my medical school journey because I was curious about the business of medicine and passionate about making a broader impact in the health care and... View Details
- June 2023
- Case
Verve Therapeutics: Taking DNA Editing to Heart
By: Shikhar Ghosh and Shweta Bagai
Verve Therapeutics, a public biotech company based in Boston, created a novel approach to addressing cardiovascular disease (CVD) - a leading cause of deaths globally. The company's approach was a single shot treatment to permanently lower cholesterol, thus reducing... View Details
Keywords: AI; Genetic Engineering; Medicine; Health Care and Treatment; Genetics; Innovation Strategy; Business and Stakeholder Relations; Medical Specialties; Innovation and Invention; Entrepreneurship; Biotechnology Industry
Ghosh, Shikhar, and Shweta Bagai. "Verve Therapeutics: Taking DNA Editing to Heart." Harvard Business School Case 823-113, June 2023.
- Web
Morgan Hall | About
stone facility housed offices for the Dean, faculty, research staff, and administrative personnel, as well as accounting laboratories, research rooms, and a laboratory of industrial physiology. Special care was taken to preserve Morgan’s... View Details
- Blog
Making the Decision to Attend: Our Participants Share Their Stories
"Overall, the experience was incredible—completely life changing. It's changed how I look at the world. It's changed how I look at myself. And it's definitely changed how I look at my organization and how we're going to be able to move ahead." Joanne Hames Manager,... View Details
- November 2020
- Teaching Note
Valuing Celgene's CVR
By: Benjamin C. Esty and Daniel Fisher
Teaching Note for HBS Case No. 221-031. When Bristol-Myers Squibb (BMS) acquired Celgene Corporation in November 2019, Celgene shareholders received cash, BMS stock, and a contingent value right (CVRs) that would pay $9 if the U.S. Food and Drug Administration (FDA)... View Details
- 13 Jul 2020
- Research & Ideas
Merck CEO Ken Frazier Discusses a COVID Cure, Racism, and Why Leaders Need to Walk the Talk
criminal justice reform, other issues like that, health care reform, but the nexus between corporate America and what Black America needs and the most, in my opinion, is employment. And so if we can do... View Details
- January 2014 (Revised December 2014)
- Case
GenapSys: Business Models for the Genome
By: Richard G. Hamermesh, Joseph B. Fuller and Matthew Preble
GenapSys, a California-based startup, was soon to release a new DNA sequencer that the company's founder, Hesaam Esfandyarpour, believed was truly revolutionary. The sequencer would be substantially less expensive—potentially costing just a few thousand dollars—and... View Details
Keywords: DNA Sequencing; Life Sciences; Business Model; Innovation & Entrepreneurship; Health Care and Treatment; Genetics; Business Strategy; Health Industry; Health Industry; Health Industry; Health Industry; Health Industry; United States
Hamermesh, Richard G., Joseph B. Fuller, and Matthew Preble. "GenapSys: Business Models for the Genome." Harvard Business School Case 814-050, January 2014. (Revised December 2014.)
- 22 Feb 2022
- News
Lack of Female Scientists Means Fewer Medical Treatments for Women
- Web
Business Fundamentals Course - CORe | HBS Online
pricing strategies Identify sources of competitive advantage through differentiation Evaluate the financial health of a business using financial statements Prepare and evaluate financial forecasts Who Will Benefit Professionals MBA... View Details
- Web
Pagliuca Harvard Life Lab | About
serving over the years as Co-Chairs of their respective MBA Class Reunion Campaigns. They are three-term members of the HBS Board of Dean’s Advisors and are currently serving as Vice Chairs for the HBS Campaign. Additionally, Steve has served on the View Details
- 19 Jul 2017
- Research & Ideas
Why Government 'Nudges' Motivate Good Citizen Behavior
Milkman, among others, the group settled on four areas of particular interest to nudge units in the United States and United Kingdom—retirement savings, college enrollment, public health interventions, and energy consumption. They then... View Details
Keywords: by Michael Blanding
- 12 Jan 2016
- First Look
January 12, 2016
link: https://www.hbs.edu/faculty/Pages/item.aspx?num=50304 October 2015 Health Affairs Exposure to Harmful Workplace Practices Could Account for Inequality in Life Spans Across Different Demographic Groups By: Goh, Joel, Jeffrey Pfeffer,... View Details
Keywords: Carmen Nobel
- 23 Mar 2023
- Research & Ideas
As Climate Fears Mount, More Investors Turn to 'ESG' Funds Despite Few Rules
Investor interest in social responsibility has skyrocketed in the past three years, even as US regulations to hold companies accountable remain in flux and the environmental, social, and governance (ESG) label itself draws backlash. Investors are willing to pay a... View Details